Core Insights - The first domestically developed gene engineering Class I new drug, human interferon α1b (Yunde Su), is showing unique potential in cancer treatment, emphasizing "Chinese wisdom" in the field [1] Group 1: Event Overview - The "2025 Annual Academic Salon of Academicians and Experts" was held by Sanyuan Gene Pharmaceutical Co., Ltd. in Beijing, focusing on the innovative application of human interferon α1b in treating malignant tumors [1] - The event was guided and funded by the Beijing Association for Science and Technology, gathering top oncology experts from various prestigious institutions [3] Group 2: Strategic Value of Old Drugs - Academician Hou Yunde, known as the "father of Chinese interferon," highlighted that while interferon is an old drug, interferon α1b is a new drug with significant advantages in cancer treatment, including the ability to improve efficacy through higher dosages and expand clinical indications [4] - Continuous innovation by clinical experts and Sanyuan Gene in new formulations and administration methods for interferon has established a high-quality brand in China [4] Group 3: Clinical Data and Research Findings - Experts shared significant research results on the efficacy of interferon α1b in treating melanoma, particularly in the context of its unique characteristics compared to Western treatments [5] - A new high-level randomized controlled clinical research plan was announced, indicating that combination therapy based on human interferon α1b is effective and safe for various types of melanoma [5] Group 4: Expert Consensus and Guidelines - The latest expert consensus on the treatment of melanoma with interferon α1b was presented, confirming its safety and efficacy through numerous cases [6] - The treatment protocol for melanoma using interferon α1b has been officially included in the 2025 edition of the Chinese Anti-Cancer Association (CACA) melanoma guidelines, marking a significant recognition of domestically developed innovative drugs [6] Group 5: Future Directions - A high-level dialogue session was held to explore future research directions and application potential of interferon α1b, showcasing the event as a platform for academic achievements and promoting the value of original research drugs in cancer treatment [7]